Evidence map›Paper›PMID 35668066›Full record

ArticleSignal transduction and targeted therapy2022

A robust reporting system for measurement of SARS-CoV-2 spike fusion efficiency.

Cong Huang, Yang Yang, Peng Yang, Fei Wang, Xinyu Li, Xiang Song, Yiming Wang, Cuiyun Yu, Xuejun Wang, Shengqi Wang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cong Huang *Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, 421001, Hengyang, China.
Yang Yang *State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Peng YangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Fei WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Xinyu LiState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Xiang SongState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Yiming WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China.
Cuiyun YuHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, 421001, Hengyang, China. yucuiyunusc@hotmail.com.
Xuejun WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China. xjwang@bmi.ac.cn.ORCID 0000-0001-5895-936X
Shengqi WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 100850, Beijing, China. sqwang@bmi.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2HumansSpike Glycoprotein, CoronavirusVirus InternalizationSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35668066
PMCPMC9169031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.